Cirius Therapeutics announces two posters on MSDC-0602K to be presented at The Liver Meeting 2018 (PRNewswire) - Nov 6, 2018 - "Cirius Therapeutics today announced the presentation of two posters further describing the activity of MSDC-0602K in diet-induced models of non-alcoholic steatohepatitis (NASH). This follows the Company's announcement of positive data from an interim analysis of its Phase 2b clinical trial of MSDC-0602K in patients diagnosed with NASH with fibrosis. These posters will be presented at the American Association for the Study of Liver Diseases (AASLD) – also known as The Liver Meeting – occurring in San Francisco, California from November 9 to 13, 2018."
P2b data • Preclinical • Fibrosis • Immunology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis
|